Dear All, To end the week, we have a really lovely paper from the Swiss Roundtable on Antibiotics (a multidisciplinary, non-profit Swiss association). Here are the links you need: The new (25 March 2024) paper entitled “Effective antibiotics for the Swiss health care system: today and in the future.” A prior (7 Feb 2023) paper
Dear All, Today’s news is that the House PASTEUR sponsors (Drew Ferguson [R-GA-3], Scott Peters [D-CA-50], Jake LaTurner [RKS-2] and Mike Levin [D-CA-49]) are urging House leadership to authorize the PASTEUR Act without initially having funding attached. Although this may seem counterintuitive, initial passage as a $0 bill is a solid strategy — it is common
Dear All, If you follow US politics, you will know that the USG (US Government) is beginning its appropriations process for FY2025 (Federal Year 2025). In preparation, a letter calling for AMR-related funding has been drafted by the Infectious Diseases Society of America (IDSA), AdvaMedDx, American Society for Microbiology (ASM), Association for Professionals in Infection Control
Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024
Dear All, This one slipped past me until just now … EMA have released a concept paper entitled “Development and manufacture of human medicinal products specifically designed for phage therapy – Scientific guideline.” Here are the links you need: Overview webpage regarding the concept paper The 4-page concept paper itself A parallel guidance on phage for veterinary purposes
This is the third of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a second (28 Sep 2023) newsletter that expands on the EPA concept note, a 4th newsletter (27 Jan 2024) containing some additional resources, and a fifth newsletter (11 Oct 2024) about the EPA’s collaborative framework for evaluating the AMR risks of antibacterial and antifungal
Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and
Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”
Update on 11 October 2023: The annual BARDA Industry Day is 13-14 November 2023! You can attend virtually or in person at the Grand Hyatt Washington, DC. Click here for more details! Dear All, Hot on the heels of the BAA from BARDA and from ARPA-H, we now have a Broad Agency Announcement from the FDA! There
This is the second of a 5-part newsletter series. There is an initial 27 Sep 2023 newsletter introducing the EPA concept note, a third (12 Jan 2024) newsletter about ending the use of streptomycin spray on citrus crops, a 4th newsletter (27 Jan 2024) containing some additional resources, and a fifth newsletter (11 Oct 2024) about the EPA’s collaborative framework for evaluating the